Literature DB >> 18725439

Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis.

Russell E Lewis1, Nathaniel D Albert, Dimitrios P Kontoyiannis.   

Abstract

In a neutropenic murine model of invasive pulmonary aspergillosis, prophylaxis with single doses of liposomal amphotericin B or micafungin at >or=5 mg/kg of body weight improved animal survival and suppressed the lung fungal burden for up to 7 days after infection, demonstrating the potential utility of infrequent dosing with these antifungals.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18725439      PMCID： PMC2573155          DOI： 10.1128/AAC.00715-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.

Authors:  Jon A Olson; Jill P Adler-Moore; Julie Schwartz; Gerard M Jensen; Richard T Proffitt
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

2.  Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis.

Authors:  Nathan P Wiederhold; Vincent H Tam; Jingduan Chi; Randall A Prince; Dimitrios P Kontoyiannis; Russell E Lewis
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

3.  Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.

Authors:  D Andes; N Safdar; K Marchillo; R Conklin
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

4.  Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.

Authors:  Arnold Louie; Mark Deziel; Weiguo Liu; Michael F Drusano; Tawanda Gumbo; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

5.  Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia.

Authors:  Tawanda Gumbo; George L Drusano; Weiguo Liu; Robert W Kulawy; Christine Fregeau; Vasha Hsu; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

6.  Murine model of invasive aspergillosis.

Authors:  Russell E Lewis; Nathan P Wiederhold
Journal:  Methods Mol Med       Date:  2005

7.  High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation.

Authors:  J El-Cheikh; C Faucher; S Fürst; S Duran; P Berger; N Vey; A-M Stoppa; R Bouabdallah; J-A Gastaut; P Viens; D Blaise; M Mohty
Journal:  Bone Marrow Transplant       Date:  2007-01-29       Impact factor: 5.483

8.  High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.

Authors:  Parinda Mehta; Alexander Vinks; Alexandra Filipovich; Gretchen Vaughn; Deborah Fearing; Christine Sper; Stella Davies
Journal:  Biol Blood Marrow Transplant       Date:  2006-02       Impact factor: 5.742

9.  Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits.

Authors:  V Petraitis; R Petraitiene; A H Groll; A Bell; D P Callender; T Sein; R L Schaufele; C L McMillian; J Bacher; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity.

Authors:  Nathan P Wiederhold; Dimitrios P Kontoyiannis; Jingduan Chi; Randall A Prince; Vincent H Tam; Russell E Lewis
Journal:  J Infect Dis       Date:  2004-09-10       Impact factor: 5.226
View more
  13 in total

1.  Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients.

Authors:  Thomas J Walsh; Sylvain Goutelle; Roger W Jelliffe; Jeffrey A Golden; Emily A Little; Catherine DeVoe; Diana Mickiene; Maggie Hayes; John E Conte
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

2.  Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis.

Authors:  Alexander J Lepak; Karen Marchillo; Jaimie Vanhecker; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

3.  Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates.

Authors:  Alexander J Lepak; Karen Marchillo; Jamie VanHecker; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

Review 4.  Extended Dosing Regimens for Fungal Prophylaxis.

Authors:  Thomas Lehrnbecher; Konrad Bochennek; Thomas Klingebiel; Silke Gastine; Georg Hempel; Andreas H Groll
Journal:  Clin Microbiol Rev       Date:  2019-05-15       Impact factor: 26.132

5.  Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.

Authors:  Luciana Annino; Anna Chierichini; Barbara Anaclerico; Erica Finolezzi; Marianna Norata; Stefania Cortese; Maria Iris Cassetta; Stefania Fallani; Andrea Novelli; Corrado Girmenia
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

6.  Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection.

Authors:  Pappanaicken R Kumaresan; Pallavi R Manuri; Nathaniel D Albert; Sourindra Maiti; Harjeet Singh; Tiejuan Mi; Jason Roszik; Brian Rabinovich; Simon Olivares; Janani Krishnamurthy; Ling Zhang; Amer M Najjar; M Helen Huls; Dean A Lee; Richard E Champlin; Dimitrios P Kontoyiannis; Laurence J N Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-07       Impact factor: 11.205

Review 7.  Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.

Authors:  Neil R H Stone; Tihana Bicanic; Rahuman Salim; William Hope
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

8.  Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem cell transplant patients.

Authors:  Paul O Gubbins; Jarrett R Amsden; Scott A McConnell; Elias J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  2009-06-22       Impact factor: 5.191

9.  Micafungin in the treatment of invasive candidiasis and invasive aspergillosis.

Authors:  Nathan P Wiederhold; Jason M Cota; Christopher R Frei
Journal:  Infect Drug Resist       Date:  2009-01-12       Impact factor: 4.003

10.  Extrapolating Antifungal Animal Data to Humans - Is it reliable?

Authors:  Victoria M Stevens; Scott W Mueller; Paul M Reynolds; Robert MacLaren; Tyree H Kiser
Journal:  Curr Fungal Infect Rep       Date:  2020-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.